Envestnet Asset Management Inc. Has $41.61 Million Stake in Merck & Co. (MRK)

Envestnet Asset Management Inc. increased its position in Merck & Co. (NYSE:MRK) by 8.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 739,549 shares of the company’s stock after purchasing an additional 59,704 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Merck & Co. were worth $41,614,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. D.A. Davidson & CO. boosted its stake in Merck & Co. by 18.3% during the 3rd quarter. D.A. Davidson & CO. now owns 524,481 shares of the company’s stock valued at $33,582,000 after acquiring an additional 81,290 shares during the last quarter. Train Babcock Advisors LLC boosted its stake in Merck & Co. by 19.8% during the 4th quarter. Train Babcock Advisors LLC now owns 10,810 shares of the company’s stock valued at $609,000 after acquiring an additional 1,785 shares during the last quarter. Ascension Asset Management LLC bought a new position in Merck & Co. during the 4th quarter valued at $644,000. Mork Capital Management LLC bought a new position in Merck & Co. during the 4th quarter valued at $990,000. Finally, Signature Financial Management Inc. boosted its stake in Merck & Co. by 13.1% during the 3rd quarter. Signature Financial Management Inc. now owns 13,432 shares of the company’s stock valued at $779,000 after acquiring an additional 1,555 shares during the last quarter. Institutional investors and hedge funds own 74.87% of the company’s stock.

Shares of NYSE:MRK opened at $59.07 on Friday. The firm has a market cap of $161.10 billion, a price-to-earnings ratio of 14.40, a price-to-earnings-growth ratio of 2.28 and a beta of 0.76. Merck & Co. has a 1-year low of $59.04 and a 1-year high of $59.65. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.10 and a current ratio of 1.42.

Merck & Co. (NYSE:MRK) last issued its earnings results on Tuesday, May 1st. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.00 by $0.05. Merck & Co. had a net margin of 4.31% and a return on equity of 30.93%. The company had revenue of $10.04 billion for the quarter, compared to analysts’ expectations of $10.09 billion. During the same period in the prior year, the company earned $0.88 earnings per share. The firm’s revenue was up 6.4% compared to the same quarter last year. equities research analysts anticipate that Merck & Co. will post 4.23 EPS for the current year.

In related news, insider Weir Mirian M. Graddick sold 24,000 shares of the stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $58.00, for a total value of $1,392,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Julie L. Gerberding sold 9,972 shares of the stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $59.66, for a total transaction of $594,929.52. The disclosure for this sale can be found here. 0.32% of the stock is owned by company insiders.

MRK has been the topic of a number of research analyst reports. ValuEngine downgraded shares of Merck & Co. from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Credit Suisse Group reduced their price objective on shares of Merck & Co. from $67.00 to $66.00 and set an “outperform” rating on the stock in a research note on Monday, February 5th. Leerink Swann reduced their price objective on shares of Merck & Co. from $69.00 to $67.00 and set a “market perform” rating on the stock in a research note on Tuesday, February 6th. Morgan Stanley increased their price objective on shares of Merck & Co. from $60.00 to $63.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. Finally, DZ Bank upgraded shares of Merck & Co. from a “hold” rating to a “buy” rating in a research note on Tuesday, February 13th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $65.87.

About Merck & Co.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply